A new Expert Consensus Decision Pathway issued by the American College of Cardiology (ACC) recommends Jardiance® (empagliflozin) as the preferred SGLT2 inhibitor for its proven benefit in reducing the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease. The recommendation, part of the ACC’s first Expert Consensus Decision Pathway on novel therapies for cardiovascular risk reduction in adults with type 2 diabetes and atherosclerotic cardiovascular disease, was released today and published online in the Journal of the American College of Cardiology.Jardiance is marketed by Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY).
The recommendation of Jardiance is based on evidence from the landmark EMPA-REG OUTCOME® trial, which investigated the effects of Jardiance compared with placebo when added to standard of care in adults with type 2 diabetes and established cardiovascular disease. In addition to the ACC Expert Consensus Decision Pathway, the American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) recommend SGLT2 inhibitors such as Jardiance to help manage cardiovascular outcomes. Jardiance is also the only SGLT2 inhibitor recommended in the ADA 2018 Standards of Medical Care in Diabetes for reducing the risk of cardiovascular death in people with type 2 diabetes and established cardiovascular disease. Worldwide, more than 50 treatment guidelines have been updated to include findings from the EMPA-REG OUTCOME trial in their endorsement of type 2 diabetes treatments with proven cardiovascular benefits.
‘People with type 2 diabetes are at an increased risk of serious cardiovascular complications and events even when their blood sugar is under control, which is why reducing cardiovascular risk in people with diabetes is critical,’ said Thomas Seck, M.D., senior vice president, Medicine and Regulatory Affairs, Boehringer Ingelheim Pharmaceuticals, Inc. ‘The ACC Expert Consensus Decision Pathway, along with the ADA and EASD, all now recommend a comprehensive cardiovascular program for adults with type 2 diabetes and established cardiovascular disease that includes a treatment such as Jardiance, shown to improve cardiovascular outcomes in this population. These recommendations reflect a fundamental change in the management of diabetes, moving beyond glucose control to a broader strategy of comprehensive cardiovascular risk reduction.’
The 2018 ACC Expert Consensus statement emphasizes the need for a collaborative treatment approach by healthcare providers to reduce cardiovascular risk and improve survival in people with type 2 diabetes, a growing public health epidemic. People with diabetes are up to four times more likely to develop cardiovascular disease than those without diabetes, and cardiovascular disease ranks as the leading cause of death associated with diabetes.
The ACC Expert Consensus Decision Pathway’s recommendation of Jardiance, along with those of the ADA and EASD, represents a shift toward a comprehensive and team-based approach for managing the overall health of people with type 2 diabetes. The ACC encourages cardiologists to work as part of a broad healthcare provider team including primary care, internal medicine and endocrinology physicians, as well as nurse practitioners, physician assistants, diabetes educators and pharmacists, to improve the care and outcomes of people with type 2 diabetes.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.